Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits

Forschende Komplementarmedizin

Volumn 13, Issue 3, 2006, Pages 156-166

  Heusser, Peter ^a,b,d   Braun, Sarah Berger ^a   Bertschy, Manuel ^b   Burkhard, René ^b   Ziegler, Renatus ^c   Helwig, Silke ^d   Van Wegberg, Brigitte ^e   Cerny, Thomas ^f  

^a Institute for Complementary Medicine KIKOM   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Institute Hiscia   (Switzerland)

^d Lukas Klinik   (Switzerland)

^e KLINIK HIRSLANDEN   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Anthroposophic medicine; CAM; Cancer treatment, palliative; Quality of life

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; CANCER PALLIATIVE THERAPY; COGNITION; EMOTION; HUMAN; MAJOR CLINICAL STUDY; QUALITY OF LIFE; SCORING SYSTEM; SOCIAL ASPECT; STATISTICAL ANALYSIS; SWITZERLAND;

ANTHROPOSOPHY; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, SPECIAL; HUMANS; MALE; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; SWITZERLAND;

EID: 33745745944     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000092448     Document Type: Article

References (76)

1. Archer VR, Billingham LJ, Cullen MH: Palliative chemotherapy; no longer a contradiction in terms. Oncologist 1999;4:470-477.
2. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:772-782.
3. Kaiser G, Birkmann S, Büschel G. Horneber M, Kappauf H, Gallmeier WM: Unkonventionelle, alternative Therapieverfahren in der Onkologie (Übersicht). Internist 1998;39:1159-1167.
4. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
5. Dobs AS, Ashar BM: Complementary and alternative medicine. Sci Am 2002;7:1-9.
6. Astin JA: Why patients use alternative medicine. JAMA 1998;279:1548.
7. Handel DL: Complementary therapies for cancer patients. What works, what doesn't, and how to know the difference. Texas Med 2001;97:68-72.
8. Kaptchuk TJ, Eisenberg DM: The persuasive appeal of alternative medicine. Ann Intern Med 1998;129:1061-1065.
9. Cassileth BR, Chapman CC: Alternative and complementary cancer therapies. Cancer 1996;77:1026-1034.
10. Salmenperä L, Suominen T, Lauri S, Paukka P: Attitudes of patients with breast and prostate cancer toward complementary therapies in Finland. Cancer Nurs 2001;24:328-334.
11. Berger DP, Obrist R, Obrecht JP: Tumorpatienten und Paramedizin. Versuch einer Charakterisierung von Anwendern und konventioneller Therapieverfahren in der Onkologie. Dtsch Med Wochenschr 1989;114:323-333.
12. Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T: Use of complementary/alternative medicine in Ontario: prevalence and perceptions. J Clin Oncol 2000;18:2515-2521.
13. Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, Shekelle P: Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2002;2:8. www.biomedcentral.com/1472-6882/2/8.
14. Von Rohr E, Pampallona S, van Wegberg B, Cerny T, Hürny C, Bernhard J, Helwig S, Heusser P: Attitudes and beliefs towards disease and treatment in patients with advanced cancer using anthroposophical medicine. Onkologie 2000;23:558-563.
15. Stole BA: Can unorthodox cancer therapy improve quality of life? Ann Oncol 1993;4:121-123.
16. Girardin DW: Integration of complementary disciplines into the oncologic clinic. Part IV. Implications for spirituality with oncology patients. Curr Probl Cancer 2000;24:268-279.
17. Steiner R, Wegman I: Fundamentals of Therapy. An Extension of the Art of Healing Through Spiritual Knowledge, ed 4. London. Rudolf Steiner Press, 1983.
18. Heusser P: A basis for the understanding of anthroposophical medicine and cancer therapy. J Anthroposophic Med 1991;8:5-38.
19. Swiss Cancer League: Swiss Cancer Helpline Statistics 1998-2002. Bern, Swiss Cancer League, 2003.
20. Hiller B: Was Krebspatienten wissen wollen. Alternative Krebstherapie seit 1991. Dtsch Arztebl 2003;100:A1182-1185.
21. Carlsson M, Arman M, Backman M, Flatters U, Hatscheck T, Hamrin E: Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. Acta Oncol 2004;43:27-34.
22. Heusser P, Berger S, Ziegler R, Bertschy M, Helwig S, van Wegberg B, Cerny T: Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns before, during and after hospitalization and subsequent treatment compliance with anthroposophic medicine. Forsch Komplementärmed 2006;13:94-100.
23. Hürny C, Heusser P, Bernhard J, Castiglione M, Cerny T: Verbessern nicht-konventionelle Zusatz-therapien die Lebensqualität von Krebspatienten? Schweiz Med Wochenschr 1994;124(suppl 62):55-63.
24. Van Wegberg B, Bacchi M, Heusser P, Helwig S, Schaad R, von Rohr E, Bernhard J, Hürny C, Castiglione M, Cerny T: The cognitive-spiritual dimension, an important addition to the assessment of quality of life: validation of a questionnaire (SELTM) in patients with advanced cancer. Ann Oncol 1998;9:1091-1096.
25. Pampallona S, von Rohr E, van Wegberg B, Bernhard J, Helwig S, Heusser P, Hürny C, Schaad R, Cerny T: Sociodemographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie 2002;24:165-170.
26. Von Rohr E, Pampallona S, van Wegberg B, Hürny C, Bernhard J, Heusser P, Cerny T: Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. Schweiz Med Wochenschr 2000;130:1173-1184.
27. Cerny T, Heusser P: Untersuchungen der Lebensqualität von Patienten mit metastasierendem Brust- oder Darmkrebs, behandelt in der Anthropsophischen Medizin oder in der Schulmedizin, letztere mit oder ohne psychoonkologische oder anthroposophische Zusatztherapie. Forsch Komplementärmed 1999;6(suppl 1):35-37.
28. Jungi WF, Senn HJ (eds): Krebs und Alternativmedizin II. Berlin, Springer, 1990.
29. Mansky PJ: Mistletoe and cancer: controversies and perspectives. Semin Oncol 2002;29:589-594.
30. Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kiene H: Mistletoe in cancer. A systematic review on controlled clinical trials. Eur J Med Res 2003;8:109-119.
31. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N: The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993;85:365-376.
32. Bullinger M, Kirchberger I, Porsolt F: Der EORTC- Lebensqualitätsfragebogen QLQ-C30. Erste psychometrische Ergebnisse einer Querschnittsuntersuchung an älteren Patienten. Z Gerontopsychol Psychiatr 1993;6:259-265.
33. Ringdal GI, Ringdal K: Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogenous diagnosis. Qual Life Res 1993;2:329-340.
34. Aaronson NK: Scoring procedures for the EORTC Core quality of Life Questionnaire (EORTC QLQ-C30). Amsterdam, The Netherlands Cancer Institute, 1994.
35. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
36. Snaith RP, Zigmond AS: Hospital Anxiety and Depression Scale. Bershire, NFER-Nelson Publishing, 1994. Authorized German translation by Brigitte van Wegberg, 1995.
37. Averbeck M, Grote-Kusch MT, Schroder A: Konzeptualisierung und Entwicklung von Skalen zur Erfassung von Lebensqualität bei Tumorpatienten (SELT). Kurzbericht. Z Klin Psychol Forsch Prax 1992;21:302-307.
38. Leiberich von P, Averbeck M, Grote-Kusch MT: Lebensqualität von Tumorkranken als multidimensionales Konzept. Z Psychosom Med 1993;39:26-37.
39. Heywood K: Introducing art therapy into the Christie Hospital Manchester UK 2001-2002. Complement Ther Nurs Midwifery 2003;9:125-132.
40. Coates AS, Hürny C, Peterson HF, Bernhard J, Castiglione M, Gelber RD, Goldhirsch A: Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 2000;18:3766-3774.
41. Flechtner H, Bottomley A: Fatigue and quality of life: lessons from the real world. Oncologist 2003; 8(suppl 1):5-9.
42. Curt GA: The impact of fatigue on patients with cancer: overview of fatigue 1 and 2. Oncologist 2000;5(suppl 2):9-12.
43. Curt G, Johston PG: Cancer fatigue: the way forward. Oncologist 2003;8(suppl 1):27-30.
44. Berger A: Treating fatigue in cancer patients. Oncologist 2003;8(suppl 1):10-14.
45. Cohen SR, Leis A: What determines the quality of life of terminally ill patients from their own perspective? J Palliative Care 2002;18:48-58.
46. Hilliard RE: The effects of music therapy on the quality and length of life of people diagnosed with terminal cancer. J Music Ther 2003;40:113-137.
47. Wilkie DJ, Kampbell J, Cutshall S, Halabisky H, Harmon H, Johnson LP, Weinacht L, Rake-Marona M: Effects of massage on pain intensity, analgesics and quality of life in patients with cancer pain: A Pilot study of a randomized clinical trial conducted within hospice care delivery. Hosp J 2000;15:31-53.
48. Mc Clain CS, Rosenfeld B, Breitbart W: Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet 2003;361:1603-1607.
49. Jordhoy MS, Fayers P, Loge JH, Ahler-Ehnquist M, Kaasa S: Quality of life in palliative cancer care: results from a cluster randomized trial. J Clin Oncol 2001;19:3884-3894.
50. Nordin K, Steel J, Hoffman K, Glimenius B: Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. Br J Cancer 2001;85:1265-1272.
51. Glimenius B, Hoffmann K, Sjöden PO, Jacobsson G, Sellström H, Enader LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
52. Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, Kvikstad A: The EORTC Core Quality of Life Questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995;31A:2260-2263.
53. Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, Maroun S, Jolivet J, Fields A, Lee IM, Moon MJ: The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a multicenter Canadian trial. Clin Colorectal Cancer 2002;2:93-101.
54. Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Lamers RJ, Slotman BJ, Wouters EF: Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 2001;19:2123-2133.
55. Doyle C, Crump M, Pintilie M, Oza AM: Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer: J Clin Oncol 2001;19:1266-1274.
56. Helsing M, Bergman B, Thaning L, Hero U: Quality of life and survival in patients with advanced non-small lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomized phase III trial. Eur J Cancer 1998;34:1036-1044.
57. Gridelli C: Does chemotherapy have role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer 2002;38(suppl 2):S45-50.
58. Hajto T, Hostanska K, Gabius HJ: Modulatory potency of the B-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 1989;49:4803-4808.
59. Büssing A, Fischer K, Schietzel M (eds): Misteltherapie und immunologische Forschung. Forsch Komplementärmed 1996;3(suppl 1).
60. Vehmeyer K, Liersch T, Damenz W, Rolf F, Siebert K, Brauneis J: Hemopoiesis protection by mistletoe extract during the therapy of head and neck tumors. J Cancer Res Clin Oncol 1990;116:697.
61. Heiny BM: Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin 1991;12:1-14.
62. Bock PR, Friedel WE, Hanisch J, Hoffmann J, Karasmann M, Scheider B: Adjuvant standardised mistletoe extract in early stage breast carcinoma - a multicentre comparative retrolective epidemiologic cohort study. Focus Altern Complement Ther 2003;8:125-126.
63. Schierholz JM, Piao Bk, Wang YX, Xie GR, Mansmann U, Matthes H, Benth J, Liu HS: Komplementäre Tumortherapie mit standardisiertem Mistelextrakt. Dtsch Z Onkol 2003;35:186-194.
64. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock P, Hanisch JR, Beuth J: Postoperative komplementäre Therapie des primären Mammakarzinoms mit lektinnormiertem Mistelextrakt - eine epidemiologische, kontrollierte, multizentrische retrolektive Kohortenstudie. Biosynthesen 2002;3:10-22.
65. King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555-567.
66. Le Fevre P, Devereux J, Smith S, Lawrie SM, Cornbleet M: Screening for psychiatric illness in the palliative care inpatient setting: a comparison between the Hospital Anxiety and Depression Scale and the General Health Questionnaire-12. Palliat Med 1999;13:399-407.
67. Holtom N, Barraclough J: Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing depression in palliative care? Palliat Med 2000;14:219-220.
68. Fulton C: Patients with metastatic breast cancer: their physical and psychological rehabilitation needs. Int J Rehabil Res 1999;22:291-301.
69. Oyama H, Kaneda M, Katsumata N, Akechi T, Ohsuga M: Using the Bedside Wellness System during chemotherapy decreases fatigue and emesis in cancer patients. J Med Syst 2000;24:173-182.
70. Van Wegberg B, Lienhard A, Andrey M: Verändert ein psychosoziales Gruppeninterventionsprogramm die Lebensqualität von Krebspatienten? Schweiz Med Wochenschr 2000;130:177-185.
71. Nagel GA: Spannungsfeld akademische Medizin-Alternativmedizin. Praxis 1998;87:942-947.
72. Nordin K, Steel J, Hofmann K, Glimenius B: Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. Br J Cancer 2001;85:1265-1275.
73. Glimenius B, Hoffmann K, Sjodén PO, Jacobsson G, Sellström H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
74. Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, Maroun S, Jolivet J, Fields A, Lee IM, Moon MJ: The palliative benefit of irinotecan in 5-florouracil-refractory colorectal cancer: its prospective evaluation by a multicenter Canadian trial. Clin Colorectal Cancer 2002;2:93-101.
75. Langendijk JA, Aaronson NK, de Jong JM, ten Velde GPM, Muller J, Lamers RI, Slotman BJ, Wouters EFM: Prospective study on quality of life before and after radiotherapy in non-small-cell lung cancer. J Clin Oncol 2001;19:2123-2133.
76. Becchetti R: Difficult conversations. The realities of end-of-life palliative care. Oncol Issues 2003;18:36-39.